Novartis Hikes Key Drug Sales Target to $18 Billion
Novartis raised its peak sales targets to $18 billion as demand for its top treatments keeps climbing.

Novartis expects major gains from its top medicines. The Swiss drugmaker raised its long-term sales target for its best drugs to $18 billion.
Patients need its treatments for leukemia and high cholesterol. Sales for its nerve medicines also keep climbing. Leadership raised the peak sales estimates for each of these core products. The company wants to prove that its strong growth will last for years.
Novartis separated from its generic pill business to focus on specialty medicines. These complex drugs bring in more cash. That steady income helps fund new lab research for future cures.
Strong demand gives Novartis a stable path forward. Everyday investors can watch these prescription numbers to see if the company hits its new goals.
Source: CNBC




